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Kaposiform haemangioendothelioma is a rare, but potentially fatal
vascular tumour of childhood. We present a case that highlights
the diagnostic and management challenges of this condition,
particularly when associated with KasabacheMerritt phenome-
non, and supports the use of sirolimus in its treatment.
© 2014 The Authors. Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/4.0/).Introduction
Kaposiform haemangioendothelioma (KHE) is a complicated and rare form of locally aggressive
vascular tumour with distinctive pathological features.1 It typically appears in infancy and childhood
with an estimated incidence of 0.7/100,000 children per year.2
When patients with KHE develop the associated KasabacheMerritt phenomenon (KMP), charac-
terised by platelet trapping and a consumptive coagulopathy, the mortality is as high as 30%.2
KHE and KMP invariably present diagnostic and therapeutic challenges, which, if not rapidly
addressed, can result in the death of the child. Hence, early recognition and prompt management is of
importance to health professionals.
We present a case of KHE with associated KMP that demonstrates the medical and surgical chal-
lenges of this condition, highlighting the need for nationally and internationally accepted guidelines
and the need for prospective clinical trials.rgery, Alder Hey Children's NHS Foundation Trust, Eaton Road, West Derby,
).
er Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic
C BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).
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A four-week-old female presented with a 12-h history of apparent bruising to the right chest and
ﬂank. There was no history of trauma. The child was normally ﬁt and well and was born by induction of
labour at 38 weeks.
Examination revealed a well child with ecchymosis involving 6% total body surface area (Figure 1).
There were no palpable masses to suggest haematoma and the overlying skin was intact.
Initial investigations revealedmild anaemia but profound thrombocytopaenia (platelets 14109/L).
A chest radiograph showed extensive soft tissue oedema in the area of interest.
Severe thrombocytopaenia continued to worsen and the child was given blood and platelet
transfusions. The D-dimer level was highly elevated at 94,768 ng/ml. The Oncology and Plastic Surgery
teams suggested a diagnosis of KHE with associated KMP, and treatment with dexamethasone was
commenced.
A biopsy was performed, conﬁrming the diagnosis of KHE, a Broviac catheter was inserted, and the
child was commenced on aspirin and weekly vincristine (0.05 mg/kg). The dexamethasone was
changed to oral prednisolone.
After 5 days, the child was showing a good clinical and haematological response andwas discharged
for daily outpatient follow-up. The lesion continued to regress with normalisation of both platelet
counts and D-Dimer levels. 4 weeks after diagnosis, the dose of prednisolone was gradually reduced
with continuing aspirin and weekly vincristine.
Despite continuing vincristine therapy, 8 weeks from presentation, there was a rebound growth of
the KHE and a rapidly worsening coagulopathy was evidenced by a D-dimer of 12,264 ng/ml and
platelets of 41  109/L. Steroid therapy was recommenced.
MRI showed the lesion extending from the mid lateral right abdominal wall into the right axilla
(Figure 2). On discussion with an interventional radiologist, it was felt that embolisation would be
technically difﬁcult and so sclerotherapy was performed. The procedure was uncomplicated, but had
limited effect.
10 weeks after initial diagnosis, the lesion was successfully embolised through the right intercostal
arteries, internal thoracic artery, and subscapular artery. The next day, the KHE was excised down to
muscle, leaving a signiﬁcant defect in the right lateral trunk (Figure 3).
Four days post-operatively, the child was recommenced on aspirin and vincristine because of
worsening coagulopathy, with platelets of 24  109/L and a D-dimer of 23,173 ng/ml. Histopathology
showed the KHE was present at the deep margin and repeat MRI showed a signiﬁcant residual tumour.
Further excision of the lesionwas felt to carry too great a morbidity because it would involve resection
of the musculature of the right lateral trunk.Figure 1. Infant at initial presentation.
Figure 2. MRI of the lesion pre-operatively.
Figure 3. Defect following surgical excision of KHE.
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three days. The anti-platelet drug, clopidogrel, was added to aspirin and prednisolone therapy, in
accordance with Consensus-Derived Practice Standards.3
Steroid therapy was having limited effect. Although not generally effective in KHE, a trial of pro-
pranolol was commenced, but this was not successful in improving the coagulopathy.
A trial of sirolimus, recently shown to be effective in the treatment of refractory KHE,4,5 was then
started. The child's general and haematological condition subsequently improved, with a reduction in
the frequency of platelet transfusions. After four weeks there was normalisation of platelet counts and
thus no further platelet transfusions required. The D-Dimer levels also showed amarked improvement.
Steroids, aspirin and clopidogrel were discontinued between six and eight weeks after the start of
sirolimus, the dose of which was adjusted to achieve therapeutic blood levels.
The trunk defect healed well by secondary intention (Figure 4). When the child was 15 months old
and after 10 months of sirolimus a trial of stopping this treatment was attempted. Two months later
this was followed by followed by clear further evidence of KMPwith a platelet count of 24109/L and a
D-dimer of 30,915 ng/ml. Sirolimus therapy was rapidly recommenced with a rapid return to normal
platelet counts. Now 2 years and 3 months after diagnosis, the KHE is controlled with sirolimus
monotherapy that is planned to continue for at least for another two years.
Figure 4. Outcome at 1-year follow-up.
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This case demonstrates the complexity and challenges of KHE complicated by KMP. The authors
propose that this condition be treated in tertiary referral centres, with access to the variety of possible
therapeutic interventions.
KHE usually presents as an indurated purple lesion with nebulous margins. In infancy these lesions
typically occur in the skin and soft tissue of the neck, extremities and trunk. However, numerous re-
ports have identiﬁed cases involving non-cutaneous areas such as retroperitoneum.2,6
Despite these tumours expressing benign histology, their aggressive behaviour can result in the
compression and inﬁltration of adjacent structures. This signiﬁcantly increases morbidity and mor-
tality, especially when associated with KMP.7
KMP is the most serious complication associated with KHE. The pathophysiology is commonly
accepted as the trapping of platelets via the abnormally proliferating endothelium of the vascular
lesion. This intralesional trapping results in secondary ingestion of clotting factors. The consumptive
coagulopathy can progress to disseminated intravascular coagulation (DIC) and often death.
Early diagnosis is a key in the treatment of KHE. The lesion can often be misdiagnosed as infantile
haemangioma,8 which generally responds well to propranolol treatment,9 but this is not the case for
KHE. Magnetic resonance imaging is the imaging modality of choice in KHE, but treatment should not
delayed by radiological investigations.3
Surgical resection, though offering a potential cure for KHE, is often not a viable option in view of
the highmorbidity andmortality due to tumour invasion of large neurovascular structures, muscle and
fascia. The option of surgical excision requires meticulous preoperative planning and the risk to beneﬁt
ratio must be carefully considered. Embolisation, either as a deﬁnitive procedure or as an adjunct
to resection, has been advocated as a therapeutic intervention, but it can be technically very
challenging.10
The aims of pharmacological treatment are to rapidly correct coagulopathy and, thereafter, decrease
tumour size. Recent consensus-derived guidelines supported the use of steroids and vincristine as ﬁrst-
line therapy when KHE is associated with KMP.3 A number of other agents were advocated, including
sirolimus. This case report adds support to the use of sirolimus, a mammalian target of rapamycin
inhibitor, and a drug that is currently being tested in a prospective clinical trial for diagnoses that
include complicated KHE. The use of the antiplatelet agents aspirin and clopidogrel is discussed
although the evidence base is limited.
The consensus-derived guidelines are based on expert opinion, and there is still a paucity of robust
literature to support them. Clinical trials are required to advance themanagement of KHE and KMP, but
the rarity of the disease means that patient numbers may limit the power of these studies.
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